A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

March 31, 2007

Conditions
Awake Fiberoptic Intubation
Interventions
DRUG

Dexmedetomidine HCL Injection

DRUG

Placebo

Trial Locations (17)

10016

New York University Medical Center, New York

10029

The Mount Sinai School of Medicine, New York

29425

Medical University of South Carolina, Charleston

33136

University of Miami Jackson Memorial Hospital, Miami

35294

University of Alabama at Birmingham, Birmingham

44195

The Cleveland Clinic Foundation, Cleveland

53295

VA Medical Center, Milwaukee

55905

Mayo Clinic Rochester, Rochester

60612

University of Illinois Medical Center at Chicago, Chicago

66160

University of Kansas Medical Center, Kansas City

75216

VA North Texas Health Care System, Dallas

76508

Scott and White Memorial Hospital, Temple

77030

The University of Texas Medical School at Houston, Houston

The University of Texas, Houston

92354

Loma Linda University Medical Center, Loma Linda

43210-1228

The Ohio State University Medical Center, Columbus

18103-6296

Lehigh Valley Hospital, Allentown

All Listed Sponsors
lead

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00383890 - A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation | Biotech Hunter | Biotech Hunter